Efficacy and Safety of Oral Roflumilast for mod-severe psoriasis Trial

Randomized (1:1) → patients assigned to roflumilast vs placebo

Double-blind → neither patients nor investigators knew assignments

Placebo-controlled → comparator group receives inactive treatment

Multicenter trial → conducted across multiple hospitals

Identify the key design features of a randomized, double-blind, placebo-controlled trial:

Randomization → balances known & unknown confounders between groups

Blinding → reduces bias in outcome assessment and patient reporting

Placebo control → isolates the true drug effect from placebo effect

Standardized protocol → reduces variability in treatment and assessment

together these minimize selection bias, performance bias, and measurement bias, increasing confidence that outcomes are due to roflumilast

How do the features of randomized, double-blind, plaebo-controlled trial features strengthen internal validity?

Population: Adults with moderate-to-severe plaque psoriasis (PASI ≥8, candidates for systemic therapy)

Intervention: Oral roflumilast 500 μg once daily

Comparator: Placebo (through week 12)

Primary endpoint: PASI75 at week 12 (≥75% reduction in disease severity)

Describe the study population, intervention, comparator, and primary endpoint and explain how these elements define the trial's clinical question:

Does oral roflumilast improve psoriasis severity compared to placebo over 12 weeks?

What is the trial's clinical question?

PASI75 results

-Roflumilast: 35% (8/23)

-Placebo: 0% (0/23)

Treatment difference: 35%

95% CI: 13% to 57%

p-value: 0.014

Interpretation:

Statistically significant (p < 0.05)

CI does not cross 0, confirming a real treatment effect

Clinically meaningful: 35% absolute improvement is substantial

Conclusion: Strong evidence that roflumilast improves psoriasis vs placebo at 12 weeks.

Interpret the primary efficacy result by analyzing PASI75 response rates, the reported p value, and the confidence interval for the treatment difference at week 12:

Primary endpoint: PASI75 at week 12

Secondary endpoints:

PASI50, PASI90, PASI100

Change in PASI, BSA, sPGA

DLQI (quality of life)

Consistency:

PASI50: 70% vs 4% (p < 0.0001)

PASI reduction: significantly greater with treatment

DLQI improved more with treatment

Secondary outcomes support the primary finding, showing consistent improvement across multiple measures.

Differentiate primary and secondary endpoints in the trial and evaluate whether the secondary outcome results are consistent with the primary endpoint findings.

Categorical outcomes (e.g., PASI75 yes/no):

→ Fisher’s exact test

✔ Appropriate because:

-Small sample size (n=46)

-Binary data

Continuous outcomes (e.g., change in PASI, DLQI):

→ ANCOVA

✔ Appropriate because:

-Adjusts for baseline differences

-Improves precision of treatment effect

Interpret categorical and continuous outcome analyses used in the trial, including Fisher's exact test and ANCOVA, and explain why each was appropriate for the data type.

Intention-to-treat (ITT):

Includes all randomized patients

Preserves benefits of randomization

Reflects real-world effectiveness

Missing data methods:

NRI (Non-responder imputation):

Missing = counted as treatment failure (conservative)

LOCF (Last observation carried forward):

Uses last available value for continuous outcomes

These methods prevent overestimation of efficacy and strengthen reliability.

Explain the role of intention-to-treat analysis and missing-data methods such as non-responder imputation and last observation carried forward in the interpretation of trial results.

Groups were well balanced:

Similar PASI (~10.6–10.9)

Similar disease duration (~16 years)

Similar prior treatments

Impact:

Reduces confounding

Supports that differences in outcomes are due to treatment

Assess baseline comparability between study groups and determine how similarities or imbalances may influence confidence in the treatment effect.

Any drug-related AE:

Roflumilast: 87%

Placebo: 61%

Common AEs: GI symptoms, weight loss, headache

Discontinuations: low (1 in each group)

Serious AEs: none during placebo-controlled phase

Interpretation:

More AEs with treatment, but mostly mild/transient

No major safety signal

Interpret the safety findings by comparing adverse event frequencies, discontinuations, and serious adverse events between treatment groups.

-Small sample size (n=46) → limited power

-Short follow-up (12 weeks primary endpoint) → limited long-term data

-Open-label extension after week 12 → introduces bias

-Limited generalizability:

Mostly male

All Caucasian population

These reduce external validity and long-term certainty.

Evaluate important limitations of the study, including sample size, short follow-up, open-label extension after week 12, and generalizability of the findings.

Authors’ claim: roflumilast is efficacious and safe Supported?

Efficacy:

Statistically significant

Clinically meaningful improvement

Consistent across endpoints

Safety:

No serious safety concerns

Mostly mild AEs

Caveats:

Small sample

Short duration

Limited diversity

Final judgment:

Yes—conclusion is supported, but should be interpreted cautiously.

This is promising early evidence, not definitive proof for widespread use.

Judge whether the authors' conclusion that oral roflumilast was efficacious and safe is supported by the data, integrating both statistical significance and clinical relevance.